|
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Assembly Biosciences Announces Plenary Lecture at HEP DART 2019
SOUTH SAN FRANCISCO, Calif., Dec. 06, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that Richard Colonno, PhD, Executive Vice President and Chief Scientific Officer Virology, will present a Plenary Lecture, “Eliminating Residual HBV Replication – A Critical Gateway to Cure” at the HEP DART Meeting on Tuesday, Dec 10, 2019 at 5:30pm HST in Kauai, HI. The presentation will include an in-depth review of interim long-term data from the ongoing Phase 2 study of ABI-H0731, Assembly’s lead core inhibitor, for the treatment of chronic Hepatitis B infection, which were reported at AASLD 2019 last month.
Following the lecture, Dr. Colonno’s slides will be available on the Events & Presentations page in the Investors section of the company's website at assemblybio.com. |
|
发表于 2019-12-7 13:22
